NASDAQ:PODD - Insulet Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$85.84 -1.79 (-2.04 %)
(As of 02/21/2019 08:29 AM ET)
Previous Close$87.63
Today's Range$85.50 - $87.77
52-Week Range$70.80 - $108.90
Volume655,348 shs
Average Volume559,998 shs
Market Capitalization$5.07 billion
P/E Ratio-186.61
Dividend YieldN/A
Beta1.57
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$463.77 million
Book Value$2.72 per share

Profitability

Net Income$-26,830,000.00

Miscellaneous

Employees857
Market Cap$5.07 billion
OptionableOptionable

Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) released its quarterly earnings data on Thursday, August, 2nd. The medical instruments supplier reported ($0.03) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.13) by $0.10. The medical instruments supplier had revenue of $124.26 million for the quarter, compared to analyst estimates of $132.89 million. Insulet had a negative return on equity of 7.63% and a negative net margin of 2.54%. The firm's revenue for the quarter was up 13.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.13) earnings per share. View Insulet's Earnings History.

When is Insulet's next earnings date?

Insulet is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Insulet.

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Monday, February 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8448313022.

What price target have analysts set for PODD?

14 brokers have issued 1-year price objectives for Insulet's stock. Their forecasts range from $81.00 to $115.00. On average, they expect Insulet's share price to reach $98.50 in the next twelve months. This suggests a possible upside of 14.7% from the stock's current price. View Analyst Price Targets for Insulet.

What is the consensus analysts' recommendation for Insulet?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 3 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.

What are Wall Street analysts saying about Insulet stock?

Here are some recent quotes from research analysts about Insulet stock:
  • 1. According to Zacks Investment Research, "Insulet has been outperforming its industry over the past year. We are encouraged by the year-over-year improvement in net loss and revenues on solid uptake of Omnipod system in the United States in the last reported quarter. Expanding global customer base also drove revenues. Furthermore, expanding gross margin buoys optimism. We are also upbeat about Insulet’s solid progress with respect to its four-pillar strategy. Further, the receipt of FDA nod for the company’s Omnipod DASH Insulin Management System boosts investor confidence. Meanwhile, management expects the shifting to direct operations in Europe to continue to mar international revenues. Moreover, Insulet is exposed to risks associated with a weaker global economy and lower reimbursement rates." (10/4/2018)
  • 2. Canaccord Genuity analysts commented, "We maintain our BUY rating on PODD following the announcement that the company has secured two new OUS distributor partnerships with Theras Group (Italy) and Nordic Infucare (Nordic countries) effective July 1, 2018. Both distributors will provide sales, marketing, and customer support in their respective regions. We are encouraged to see PODD not only executing on OUS transition milestones but securing experienced medical device distributors in OUS countries. We believe the market exit by JNJ/Animas has created a unique opportunity for pump players – basically everyone ex Medtronic – to step into existing distribution/service networks who were left looking for new products when JNJ announced it was shuttering Animas. Thus, while not underestimating the resources required to build out an OUS commercial organization, the news of these two partnerships leaves us incrementally confident in Insulet’s ability to facilitate a smooth OUS transition." (5/2/2018)

Has Insulet been receiving favorable news coverage?

Headlines about PODD stock have been trending positive on Thursday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Insulet earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of Insulet's key competitors?

Who are Insulet's key executives?

Insulet's management team includes the folowing people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Michael L. Levitz, Sr. VP, CFO & Treasurer (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Dr. Aiman Abdel-Malek, Exec. VP & Chief Technology Officer (Age 61)

Who are Insulet's major shareholders?

Insulet's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (2.95%), Eagle Asset Management Inc. (0.94%), KAMES CAPITAL plc (0.80%), First Trust Advisors LP (0.78%), Lord Abbett & CO. LLC (0.66%) and Victory Capital Management Inc. (0.61%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, James C Mullen, Jessica Hopfield, John A Fallon, Joseph S Zakrzewski, Michael P Spears, Regina O Sommer and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

Which major investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Frontier Capital Management Co. LLC, Think Investments LP, Victory Capital Management Inc., Columbus Circle Investors, KAMES CAPITAL plc, Chartwell Investment Partners LLC and Triodos Investment Management BV. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael P Spears and Shacey Petrovic. View Insider Buying and Selling for Insulet.

Which major investors are buying Insulet stock?

PODD stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Standard Life Aberdeen plc, Jennison Associates LLC, Amundi Pioneer Asset Management Inc., New York State Common Retirement Fund, California Public Employees Retirement System, Timpani Capital Management LLC and Sit Investment Associates Inc.. Company insiders that have bought Insulet stock in the last two years include Bradley A Thomas, Charles Alpuche, James C Mullen, Jessica Hopfield and Michael P Spears. View Insider Buying and Selling for Insulet.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $85.84.

How big of a company is Insulet?

Insulet has a market capitalization of $5.07 billion and generates $463.77 million in revenue each year. The medical instruments supplier earns $-26,830,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Insulet employs 857 workers across the globe.

What is Insulet's official website?

The official website for Insulet is http://www.insulet.com.

How can I contact Insulet?

Insulet's mailing address is 600 TECHNOLOGY PARK DRIVE SUITE 200, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


MarketBeat Community Rating for Insulet (NASDAQ PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  524 (Vote Outperform)
Underperform Votes:  456 (Vote Underperform)
Total Votes:  980
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel